Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $19.25, for a total value of $82,062.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $304,762.50.

Crispr Therapeutics AG (CRSP) traded up $0.01 during mid-day trading on Thursday, reaching $18.53. The company’s stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The business had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.77) EPS. equities analysts expect that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of equities research analysts have commented on CRSP shares. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Chardan Capital reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. SunTrust Banks reissued a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Barclays reissued a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research note on Friday, September 8th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $22.38.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Granahan Investment Management Inc. MA boosted its holdings in shares of Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares in the last quarter. Allianz Asset Management GmbH purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at about $2,384,000. Credit Suisse AG purchased a new stake in Crispr Therapeutics during the 1st quarter valued at about $1,742,000. Adams Street Partners LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at about $1,019,000. Finally, Hershey Trust Co. purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at about $768,000. Institutional investors and hedge funds own 24.55% of the company’s stock.

WARNING: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-corp-de-celgene-sells-4263-shares.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.